---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-21-100078"
form_type: "8-K"
ticker: "PTGX"
cik: "0001377121"
company_name: "Protagonist Therapeutics, Inc"
filed_at: "2021-08-04T23:59:59+00:00"
generated_at: "2026-06-29T22:27:17.097016+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Protagonist Q2 net loss $30.8M; rusfertide gets FDA Breakthrough Therapy; Phase 3 on track

## Summary
- Net loss $30.8M ($0.69/share) vs $19.4M ($0.59) in Q2 2020; cash $380.4M expected to fund through 2024.
- Rusfertide granted FDA Breakthrough Therapy for polycythemia vera; Phase 3 start expected early 2022.
- Janssen collaboration amended: Janssen leads worldwide development; Protagonist eligible for ~$900M milestones plus $80M received.
- Completed public offering of 3.5M shares at $37.75, raising ~$132.2M gross proceeds.
- PN-943 Phase 2 data for ulcerative colitis anticipated in Q2 2022.

## SEC filing metadata
- accession: 0001104659-21-100078
- form_type: 8-K
- ticker: PTGX
- cik: 0001377121
- company_name: Protagonist Therapeutics, Inc
- filed_at: 2021-08-04T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1377121/000110465921100078/0001104659-21-100078-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1377121/000110465921100078/tm2124049d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-21-100078
- JSON: https://secwatch.observer/filing/0001104659-21-100078.json
- Plain text: https://secwatch.observer/filing/0001104659-21-100078.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.